Chinese Drugmaker Hit with $5.2 Million Fine Over Legacy Governance Violations
Listen to the full version
A Chinese drugmaker is confronting the fallout of misconduct under its previous ownership, as regulators slapped it with a hefty fine and a stock market risk warning for a series of violations that occurred before a state-led overhaul.
Shanghai-listed Humanwell Healthcare (Group) Co. Ltd. disclosed Saturday that it received a notice from Hubei securities authorities imposing penalties totaling 36.7 million yuan ($5.2 million) on the company, its troubled former parent, and several executives for misconduct including hiding billions of yuan in misappropriated funds. Due to financial reporting irregularities, Humanwell’s stock will be marked with a “special treatment” or “ST” label beginning Dec. 16, limiting daily trading to 5%.
The panelties finalize a reckoning with past abuses committed when Humanwell was controlled by Wuhan Dangdai Science & Technology Industries Group Co. Ltd., a large private conglomerate that collapsed under heavy debt and entered bankruptcy restructuring in September 2024.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- RELATED
- DIGEST HUB
Digest Hub
Back
- Humanwell Healthcare was fined 36.7 million yuan for misconduct such as hiding misappropriated funds and falsifying earnings under previous owner Dangdai.
- Humanwell funneled up to 12.8 billion yuan to its parent via undisclosed transactions and misstated profits by over 300 million yuan between 2020 and mid-2022.
- The company is now state-controlled, and its stock is under special market risk warning; most penalties to Dangdai will not be paid due to bankruptcy laws.
- Humanwell Healthcare (Group) Co. Ltd.
- Humanwell Healthcare (Group) Co. Ltd. (人福医药集团股份有限公司) is a Chinese drugmaker that recently faced significant penalties due to misconduct under its previous ownership. It was fined for violations including hiding billions in misappropriated funds and financial reporting irregularities. The company is now under state-owned control, owned by a subsidiary of China Merchants Group Ltd., and has corrected the misconduct.
- Wuhan Dangdai Science & Technology Industries Group Co. Ltd.
- Wuhan Dangdai Science & Technology Industries Group Co. Ltd. was the former parent company of Humanwell Healthcare. It is a large private conglomerate that collapsed under heavy debt, entering bankruptcy restructuring in September 2024. It was fined 9 million yuan for misconduct, including misappropriating 12.8 billion yuan from Humanwell.
- China Merchants Life Science (Wuhan) Co. Ltd.
- China Merchants Life Science (Wuhan) Co. Ltd. is a subsidiary of China Merchants Group Ltd., a central state-owned enterprise. It is the current owner of Humanwell Healthcare (Group) Co. Ltd., having taken control as part of a court-supervised restructuring that placed Humanwell under state ownership in August. This change occurred after Humanwell's previous parent, Wuhan Dangdai Science & Technology Industries Group Co. Ltd., collapsed due to heavy debt.
- China Merchants Group Ltd.
- China Merchants Group Ltd. is a central state-owned enterprise and the current ultimate parent company of Humanwell Healthcare (Group) Co. Ltd. Humanwell is now operated under state-owned control through China Merchants Life Science (Wuhan) Co. Ltd., a subsidiary of China Merchants Group Ltd. This change came about after Humanwell's former parent, Wuhan Dangdai Science & Technology Industries Group Co. Ltd., collapsed due to debt.
- Wuhan Kemeilide Biomedical Co. Ltd.
- Wuhan Kemeilide Biomedical Co. Ltd. is a company closely tied to Wuhan Dangdai Science & Technology Industries Group Co. Ltd. Humanwell Healthcare's subsidiaries purchased property from Wuhan Kemeilide for 1.7 billion yuan in March 2022. This transaction was in violation of regulatory rules because it was not disclosed as a related-party deal, despite the close ties between Wuhan Kemeilide and Dangdai.
- 2020：
- Humanwell funneled 2.5 billion yuan to Dangdai.
- 2021：
- Humanwell funneled 8.18 billion yuan to Dangdai.
- March 2022：
- Four Humanwell subsidiaries paid 1.7 billion yuan for property from Wuhan Kemeilide Biomedical Co. Ltd., a related-party transaction that was not disclosed as required.
- March 2022：
- Humanwell paid 100 million yuan to buy a 40% stake in a subsidiary from a nominee shareholder representing Dangdai, relationship was deliberately hidden.
- April 2022：
- Humanwell repaid the principal and interest of the funds misappropriated to Dangdai.
- First quarter of 2022：
- Humanwell funneled 2.1 billion yuan to Dangdai.
- By first half of 2022：
- Humanwell overstated net profit by more than 300 million yuan using off-balance-sheet entities.
- September 2024：
- Wuhan Dangdai Science & Technology Industries Group Co. Ltd. entered bankruptcy restructuring.
- August 2025：
- Humanwell formally came under state control, with China Merchants Group stepping in as part of a court-supervised restructuring.
- December 14, 2025：
- Humanwell disclosed it received penalties totaling 36.7 million yuan from Hubei securities authorities.
- December 16, 2025：
- Humanwell’s stock will be marked with a “special treatment” (ST) label, limiting daily trading to 5%.
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新